- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NAACOS Continues Pushing Forward on the Transition to Value-Based Care
Allison Brennan, MPP, discusses legislation that would affect accountable care organizations (ACOs), the impact coronavirus disease 2019 had on ACOs, and the fall National Association of ACOs meeting.
The move to value-based care has been a long process in the United States, perhaps made even longer by policies that some view as discouraging providers and health systems from participating in alternative payment models and now a pandemic that may stall the transition. As a result of coronavirus disease 2019 (COVID-19), CMS announced it would stop accepting applications for new accountable care organizations in 2021.
However, the National Association of ACOs (NAACOS) is still pushing forward. The organization is supporting new legislation in the House of Representatives that would update Medicare’s ACO program and reward participating ACOs.
Allison Brennan, MPP, senior vice president of government affairs at NAACOS, discusses the new Value in Health Care Act, how other policy changes at CMS have impacted ACOs, and the effect COVID-19 has had on ACOs.
Listen above or through one of these podcast services:
Learn more:
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More
Year-End Spending Bill to Feature Reforms for Pharmacy Benefit Managers and Telehealth Access
December 18th 2024The health care provisions include key reforms targeting pharmacy benefit managers, extensions of Medicare telehealth flexibilities, and measures aimed at combating the opioid crisis and preparing for future pandemics.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
